What is MBX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 2.42B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MBX?

P/E (TTM) is n/a and 52-week range is $14.61 to $72.64 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MBX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MBX?

The company profile lists net income (TTM) near -$116M, EPS (TTM) near -$2.41 when available from the market-data feed. Figures are informational and may lag live markets.

Where is MBX Biosciences, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Carmel, Indiana, US, 48.2M shares outstanding, ISIN US55287L1017 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

MBX Biosciences, Inc.

$MBX

Health Care · Pharmaceuticals

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. The company is headquartered in Carmel, Indiana and currently employs 63 full-time employees. The company went IPO on 2024-09-13. The company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets and proven endpoints for regulatory approval. Its pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in Phase III development and an obesity portfolio that includes MBX 4291 in Phase I development and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. Its lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent glucagon-like peptide 1 (GLP-1) / glucose-dependent insulinotropic polypeptide (GIP) co-agonist prodrug with the goal of potential once-monthly dosing frequency.

Employees

Website

mbxbio.com/

IPO

2024-09-13

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US55287L1017

Headquarters

Carmel, Indiana, US

Shares outstanding

48.2M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

95.52%

Browse other companiesFree AI scores and summaries for more stocks